TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01933763
Drug: REGN1193
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01706315
Drug: GSK2140944
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2140944 will be available as immediate release capsules of dose strength 100 mg and 500 mg
Study: NCT01706315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be available
Study: NCT02621944
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants 1-10 will receive a 0.5 mg/kg enteral dose of Melatonin. Participants 11-20 will receive Melatonin dose of 3 mg/kg enteral. Participants 21-30 will receive Melatonin dose of 5 mg/kg enterally.
Study: NCT00437073
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine 2000mg/m2/day orally, Days 1-14, every 21 days
Study: NCT02810392
Drug: Intranasal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delivery is with the Vianase device, 0.5 cc of normal saline
Study: NCT00299013
Drug: COLAL-PRED®
Approvals — FDA: no, EMA: no, PMDA: no
Description: COLAL-PRED 40, 60 or 80mg oral capsule, once daily for 8 weeks.
Study: NCT00299013
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 40mg oral tablets, once daily, dose tapering weekly (40,40,30,20,15,10,5,0mg) over 8 weeks.
Study: NCT04412746
Drug: MANAGEMENT OF COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: MANAGEMENT OF COVID-19 Oxygen therapy to maintain SpO2 target more than 94%. Low molecular weight heparin (LMWH) at preventive doses. Empirical antibiotic treatment.~Specific treatment for COVID-19 (approved by Algerian Ministry of Health) First line: Hydroxychloroquin: 200 mg oral three times a day for 10 days, with association of Azithromycin 250 mg oral : 500 mg the first day and 250 mg once a day for 4 days. Sulfate de Zinc : 220 mg once a day for 5 days. Second line: Lopinavir/ritonavir capsule 200 mg/50 mg, oral 2 capsules each times, twice a day during 5 to 7 days.~IF AGGRAVATION OR CRITICAL ILL CONDITION AT PRESENTATION Increase oxygenation flow. Consider Glucocorticoids. 3. Consider the diagnosis of pulmonary embolism and treat with LMWH at therapeutic doses.~MANAGEMENT OF DIABETES Discontinue metformin. Start or adjust insulin doses according to personalized glycemic target of patient.
Study: NCT04584008
Drug: FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to the treatment dose approved by NMPA/FDA, evaluation will be conducted every 2 cycles until tumor progression or adverse events cannot be tolerated.
Study: NCT04584008
Drug: Other Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive other treatments, including cytotoxic drugs, antiangiogenic drugs, best supportive care, clinical trials of unmatched new drugs, etc..
Study: NCT00362115
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets, orally, once daily for up to 8 weeks.
Study: NCT04665895
Drug: FLOVENT DISKUS® 100 mcg/blister oral inhalation powder/GSK
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily inhalation throughout the study
Study: NCT04665895
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily inhalation throughout the study
Study: NCT03682484
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00553969
Drug: placebo and placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule once daily for 9 months; dosage unknown
Study: NCT00835354
Drug: CEFZIL® for Oral Suspension 250 mg/5mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 250 mg/5 mL, single-dose fasting
Study: NCT03510715
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet,~Route of administration: oral
Study: NCT03510715
Drug: Fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule,~Route of administration: oral
Study: NCT03510715
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet,~Route of administration: oral
Study: NCT03510715
Drug: Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet,~Route of administration: oral
Study: NCT03510715
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: tablet,~Route of administration: oral
Study: NCT01092650
Drug: Deuterated phenanthrene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deuterated phenanthrene 10 micrograms
Study: NCT03997500
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: a bolus of normal saline was given followed by normal saline infusion
Study: NCT03997500
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a bolus of norepinephrine was given followed by norepinephrine infusion
Study: NCT02757768
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received initial dose of 25 mg of matching placebo (oral tablet) which was increased to 50 mg after 4 weeks.
Study: NCT02429895
Drug: ABT-122
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection
Study: NCT01128595
Drug: FF/GW642444M
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01128595
Drug: GW642444M
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01128595
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01532648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching budesonide MMX placebo oral tablet taken daily in the morning after breakfast.
Study: NCT04411199
Drug: D-PLEX
Normalized name: Kleer Plex
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-PLEX is a new formulation of extended release of Doxycycline. Each 5g D-PLEX vial contains 54.6mg Doxycycline free base (1.09%), which is equivalent to 63mg Doxycycline hyclate (1.26%). D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable.
Study: NCT01857232
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator
Study: NCT01857232
Drug: APD403 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride IV 20 mg
Study: NCT01857232
Drug: APD403 oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride oral 10, 20 or 40 mg
Study: NCT02929420
Drug: Xiaoru Sanjie capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medication for a total of 90 days. According to the instructions, P.O., three times a day, each time three tablets, take a month as a treatment course, continuous use of 3 courses.
Study: NCT00775671
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill by mouth daily for 21 days followed by either Nebivolol 5 mg by mouth daily or metoprolol ER 100mg by mouth daily for 12 weeks.
Study: NCT02723669
Drug: AR10
Normalized name: ADHESIVE DISC,DBL-FACED 1.5IN MAR107-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: effervescent tablet
Study: NCT02730169
Drug: BGS649
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules were taken weekly for a maximum of 24 weeks
Study: NCT02730169
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules were taken weekly for a maximum of 24 weeks
Study: NCT01147029
Drug: angiogenesis inhibitor GSAO
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00432107
Drug: APO866
Approvals — FDA: no, EMA: no, PMDA: no
Description: APO866 is administered as 0.126 mg/m²/hr IV every 4 weeks for 4 consecutive days (96 hours) for a total of 3 cycles
Study: NCT02371889
Drug: Inactive Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In capsules indistinguishable from topiramate capsules and gradually increased to a maximum equivalent of 200 mg of topiramate/day
Study: NCT04883203
Drug: Vit-D 0.2 MG/ML Oral Solution [Calcidol]
Normalized name: vit-D 0.2 MG/ML Oral Solution [Calcidol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARM 1 : Cholecalciferol 200,000 IU / 1 mL .
Study: NCT04883203
Drug: Physiological Irrigating Solution
Normalized name: physiological irrigating solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARM 2 : placebo
Study: NCT01644331
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV furosemide plus oral placebo (given at 0, 24 and 48 hours)
Study: NCT05058443
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo subcutaneously every 6 months (Q6M)
Study: NCT03814291
Drug: IBI302
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05mg/eye;Intraocular injection
Study: NCT01661595
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 capsule per day for four weeks.
Study: NCT04414943
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For women in this group, placebo (20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. They will be monitored for 60 minutes and then sent back to the ward.
Study: NCT03814291
Drug: IBI302
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15mg/eye;Intraocular injection
Study: NCT03814291
Drug: IBI302
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5mg/eye;Intraocular injection
Study: NCT03814291
Drug: IBI302
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg/eye;Intraocular injection
Study: NCT03814291
Drug: IBI302
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mg/eye;Intraocular injection
Study: NCT03814291
Drug: IBI302
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4mg/eye;Intraocular injection
Study: NCT01756456
Drug: rhNGF 10 μg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)
Study: NCT01756456
Drug: rhNGF 20 μg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
Study: NCT01916629
Drug: Photocil for Psoriasis
Normalized name: MG 217 Psoriasis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photocil for Psoriasis
Study: NCT03033784
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive an intranasal placebo to match the oxytocin doses.
Study: NCT01235637
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dosage form: injectable drug, opioid analgesic morphine, intravenous drug.~Dosage: intravenous drug to 0,15 µg/Kg : Blisters of 10 ml, box of 20. MERCK~Frequency and duration: 2 bolus injection before 2 tracheal suctions at 0 and 4 hours respectively.
Study: NCT00434941
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00459550
Drug: GSK933776
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A planned doses cohort 1 to cohort 3 0.001 mg/kg, 0.01 mg/kg and 0.1 mg/kg.~Part B planned doses cohort 4 to cohort 7 0.1 mg/kg, 1mg/kg, 3mg/kg and 10 mg/kg
Study: NCT00459550
Drug: Placebo to match GSK933776
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A first 2 cohorts 5 patients per cohort 2 placebo and 3 active third cohort part A 2 placebo 6 active. Part B 8 patients per cohort 2 placebo 6 active.
Study: NCT00583154
Drug: BLI-801
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1
Study: NCT00583154
Drug: BLI-801
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 2
Study: NCT00583154
Drug: BLI-801
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 3
Study: NCT00583154
Drug: BLI-801
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 4
Study: NCT01630109
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo capsule made to look like the metoclopramide capsule.
Study: NCT04632862
Drug: DWP16001
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP16001 A mg
Study: NCT01282398
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The experimental group will take 40 mg each 24 hours for at least two years.
Study: NCT01282398
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the control group wiil take placebo pills for at least two years.
Study: NCT02500836
Drug: Placebo Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
Study: NCT00228956
Drug: pharmacodynamic analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25mg po daily or Letrozole 2.5mg po daily
Study: NCT02133872
Drug: Minocycline dose escalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive minocycline 50mg if no mean daytime ABPM SBP decline =/\> 5mm Hg; subjects will receive minocycline 100mg, if no mean daytime ABPM SBP decline =/\> 5mm Hg BP subjects will receive minocycline 200 mg.
Study: NCT03809000
Drug: GnRH analog
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection
Study: NCT01798225
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received mechanical periodontal therapy, oral hygiene instructions and placebo pills.
Study: NCT01798225
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received mechanical periodontal therapy, oral hygiene instructions and Doxycycline 100mg x 14 pills (to be taken one a day for 14 days)
Study: NCT03562156
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo capsule
Study: NCT02445911
Drug: KQ-791
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules administered orally
Study: NCT02445911
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules administered orally
Study: NCT01661673
Drug: EVP-0962
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arms: 1,2,3,4
Study: NCT01661673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 5
Study: NCT02790736
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inactive pill
Study: NCT00864279
Drug: Zyrtec® 10 mg tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Pfizer Inc. formulated products under fast conditions
Study: NCT00246103
Drug: Cyclophosphamide.
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For breast cancer participants treated at MTD of Valproic acid and Epirubicin: cyclophosphamide 500 mg/m\^2.
Study: NCT01356940
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical placebo tablet administered bid for four weeks
Study: NCT00668642
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo
Study: NCT00836706
Drug: clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg Tablet
Study: NCT00836706
Drug: BIAXIN®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg Tablet
Study: NCT03955978
Drug: TSR-042
Approvals — FDA: no, EMA: no, PMDA: no
Description: -TSR-042 is administered intravenously via a 30-minute (-5-minute/+15-minute infusion window allowed) infusion
Study: NCT02568319
Drug: LIPO-202
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02568319
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02136992
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo will be taken two tablets 3 times a day during the whole study process
Study: NCT02367885
Drug: TAK-850 0.5 mL injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-850 injection
Study: NCT02367885
Drug: TAK-850 0.25 mL injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-850 intramuscular injection
Study: NCT01322152
Drug: irinotecan, capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan: 90 mg/m2, d1, iv gtt; Capecitabine: 1200mg/m2 Bid, d1-5, po; The regimen is repeated every 7 days.
Study: NCT00104884
Drug: Depsipeptide
Normalized name: palmitoyl dipeptide-7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03164993
Drug: Pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy
Study: NCT03164993
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy
Study: NCT03766399
Drug: AZD0449
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single inhaled AZD0449 nebulizer suspension and single IV dose of AZD0449 solution.
Study: NCT03766399
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single dose of placebo for AZD0449 (nebulizer suspension).
Study: NCT06643221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy participants will consume the placebo 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
Study: NCT02758626
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder formulation
Study: NCT02808611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04418154
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Take cyclophosphamide (600mg/m2, d1) every 14 days as one cycle for 4 cycles with epirubicin hydrochloride, followed by nanoparticlealbumin-bound paclitaxel and Toripalimab.
Study: NCT01373411
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 pill BID for 90 days
Study: NCT03007381
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham comparator
Study: NCT01106898
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01746992
Drug: Doxorubicin 50mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: day 1
Study: NCT00800215
Drug: iv SPM 927 and oral placebo tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-minute infusion iv SPM 927 and oral placebo tablet
Study: NCT00800215
Drug: iv SPM 927 and oral placebo tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-minute infusion iv SPM 927 and oral placebo tablet
Study: NCT00800215
Drug: oral SPM 927 tablet and iv placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-minute infusion placebo and oral SPM 927 tablet
Study: NCT01746992
Drug: methotrexate 1500mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: day 43
Study: NCT01199289
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection.
Study: NCT00004984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for oral insulin
Study: NCT02120261
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigger point injection (TPI) with 1 mL of normal saline solution. Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
Study: NCT02636868
Drug: nCPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal CPAP
Study: NCT03189719
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to pembrolizumab (saline) administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
Study: NCT02748798
Drug: HP 3He
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3He will be hyperpolarized using a custom-built polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of helium gas.
Study: NCT02748798
Drug: HP 129Xe
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: 129Xe will be hyperpolarized using a Xemed polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of xenon gas.
Study: NCT01678365
Drug: ceftriaxone, metronidazole/ampicillin, gentamicin, and metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01046994
Drug: antidiabetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients are treated with conventional antidiabetic drugs according to the rules of good clinical practice
Study: NCT00121966
Drug: Insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00949039
Drug: Isolated pelvis perfusion
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection of TNF-α 0.3 mg followed 5 minutes later by melphalan 1,5mg/kg
Study: NCT03078231
Drug: Mydriatic Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered mydriatic medication to dilate their pupils.
Study: NCT02679274
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intramuscular injections of saline (males and females).
Study: NCT02679274
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent intramuscular injections of 100 mg Testosterone Enanthate (males) or 25 mg Testosterone Enanthate (females).
Study: NCT02781558
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100 mg FDC tablet administered orally once daily
Study: NCT03272321
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray
Study: NCT02123355
Drug: Sevoflurane, remifentanil ,vecuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane（1%-2%）is inspirated, and remifentanil 0.1-0.5μg/kg//min is continuously pumped,vecuronium 0.03 mg/kg is injected intermittently.
Study: NCT02123355
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.